CUMULUS NEUROSCIENCE LIMITED

Cumulus Neuroscience Limited is a pioneering Irish‑based biotech firm that has created NeuLogiq®, the world’s most advanced at‑home, medical‑grade platform for collecting and analysing functional brain‑health data. Built in partnership with leading global pharmaceutical companies, NeuLogiq combines a 510(k)‑cleared, flexible EEG headset with tablet‑based cognitive assessments, facial‑expression analysis, speech‑processing tools and remote sleep monitoring, all synchronised to a secure cloud and powered by proprietary machine‑learning analytics.

The platform delivers frequent, reliable longitudinal measurements of cognition, neuronal integrity, network connectivity and emotional bias, enabling more precise stratification, earlier diagnosis and real‑time monitoring of central nervous system disorders. By turning rich, multi‑dimensional real‑world data into actionable insights, NeuLogiq accelerates CNS drug development, reduces trial costs and brings life‑changing therapies to patients faster.

Cumulus’s team of 30 engineers, scientists and business professionals, led by CEO Tina Sampath and a board that includes a dedicated pharma advisory consortium, works closely with pharmaceutical partners to embed NeuLogiq into clinical trials and healthcare settings worldwide.